Research Report
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1078-1087
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1078
Figure 1
Figure 1 HLA-DR, CD163 and CD36 surface expression on (CD14+/CD16-) blood classical monocytes in patients with primary non-small cell lung cancer compared to controls. A-F: Representative flow cytometry dot plots from PBMC stained against CD14, CD45 and CD16 and then co-stained with HLA-DR, CD163 and CD36 on patients with non-small cell lung cancer (red colour) and non-cancer controls (green colour).